Evidence map›Paper›PMID 39062860›Full record

ArticleInternational journal of molecular sciences2024

Analysis of the Actions of RARγ Agonists on Growing Osteochondromas in a Mouse Model.

Sonia A Garcia, Kimberly Wilson, Ningfeng Tang, Hongying Tian, Takeshi Oichi, Aruni T Gunawardena, Michael Chorny, Ivan S Alferiev, John E Herzenberg, Vincent Y Ng and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of molecular sciences, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sonia A GarciaDepartment of Orthopaedics, School of Medicine, University of Maryland, Baltimore, MD 21201, USA.
Kimberly WilsonDepartment of Orthopaedics, School of Medicine, University of Maryland, Baltimore, MD 21201, USA.
Ningfeng TangDepartment of Orthopaedics, School of Medicine, University of Maryland, Baltimore, MD 21201, USA.
Hongying TianDepartment of Orthopaedics, School of Medicine, University of Maryland, Baltimore, MD 21201, USA.
Takeshi OichiDepartment of Orthopaedics, School of Medicine, University of Maryland, Baltimore, MD 21201, USA.
Aruni T GunawardenaDepartment of Biomechanics, Northeast College of Health Sciences, Seneca Falls, NY 13148, USA.
Michael ChornyDepartment of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.ORCID 0000-0002-8243-9089
Ivan S AlferievDepartment of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA 19104, USA.ORCID 0000-0002-7849-750X
John E HerzenbergInternational Center for Limb Lengthening, Rubin Institute for Advanced Orthopedics, Sinai Hospital of Baltimore, Baltimore, MD 21215, USA.ORCID 0000-0002-6650-9251
Vincent Y NgDepartment of Orthopaedics, School of Medicine, University of Maryland, Baltimore, MD 21201, USA.
Masahiro IwamotoDepartment of Orthopaedics, School of Medicine, University of Maryland, Baltimore, MD 21201, USA.
Motomi Enomoto-IwamotoDepartment of Orthopaedics, School of Medicine, University of Maryland, Baltimore, MD 21201, USA.

Funding

Regulation of Skeletal Growth by Nuclear Retinoid ReceptorsR01AR056837 · NIAMS · UNIVERSITY OF MARYLAND BALTIMORE · PI IWAMOTO, MASAHIRO, PACIFICI, MAURIZIO · 2009 to 2020
$3.4M
Local Control of endochondral ossification by retinoid-loaded nano-particlesR01AR072713 · NIAMS · UNIVERSITY OF MARYLAND BALTIMORE · PI CHORNY, MICHAEL, IWAMOTO, MASAHIRO · 2018 to 2022
$1.8M
Development of Pharmacological Treatment of OsteochondromasR01AR073181 · NIAMS · UNIVERSITY OF MARYLAND BALTIMORE · PI ENOMOTO-IWAMOTO, MOTOMI · 2019 to 2023
$1.5M
NIAMS NIH HHS R01 AR056837NIAMS NIH HHS R01 AR072713NIAMS NIH HHS R01 AR073181NIH HHS 1R01TW073181-05A1NIH HHS 2R01AR056873-05A1
6 · The paper itself

Abstract

The actions of the retinoic acid nuclear receptor gamma (RARγ) agonist, palovarotene, on pre-existing osteochondromas were investigated using a mouse multiple osteochondroma model. This approach was based on the knowledge that patients often present to the clinic after realizing the existence of osteochondroma masses, and the findings from preclinical investigations are the effects of drugs on the initial formation of osteochondromas. Systemic administration of palovarotene, with increased doses (from 1.76 to 4.0 mg/kg) over time, fully inhibited tumor growth, keeping the tumor size (0.31 ± 0.049 mm

Indexed as

ChondrocytesDisease Models, AnimalOsteochondromaReceptors, Retinoic AcidRetinoic Acid Receptor gammaAnimalsBone NeoplasmsCell ProliferationMaleMiceSTAT3 Transcription FactorReceptors, Retinoic AcidRetinoic Acid Receptor gammaSTAT3 Transcription Factorcartilage tumorchondrocytesosteochondromapalovaroteneretinoic acid nuclear receptor gamma

Identifiers

PMID39062860
PMCPMC11277217

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.